NICKIE STEWART: Open Payments
NPI 1346725090 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$573 in 30 payments from 17 companies in 2025. Trend: 2023 $222 · 2024 $106 · 2025 $573
Food & beverage: $573
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $87 |
| Lilly USA, LLC | 4 | $70 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $38 |
| Novo Nordisk Inc | 2 | $37 |
| Acella Pharmaceuticals, LLC | 2 | $36 |
| Exact Sciences Corporation | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Lundbeck LLC | 1 | $25 |
Products named: REXULTI, MOUNJARO, AIRSUPRA, CAPLYTA, NP Thyroid 60, Ohtuvayre, XIFAXAN, Korlym.
Industry payments across TX — which companies pay providers there.
